lupus Archives -

AstraZeneca’s Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus

AZ’s lupus drug Saphnelo cleared in EU, challenging GSK’s Benlysta

https://pharmaphorum.com/news/azs-saphnelo-is-cleared-in-eu-challenging-gsks-benlysta/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

FDA approves AZ’s anifrolumab, ending 10-year lupus drug drought

Phil Taylor anifrolumab, AstraZeneca, fda, lupus, lupus nephritis, regulatory approval, Saphnelo 0 Comment

AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval

FDA approves AZ’s anifrolumab, ending 10-year lupus drug drought

https://pharmaphorum.com/news/fda-approves-azs-anifromulab-ending-10-year-lupus-drug-drought/

News/ News/ R&D

Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy

Phil Taylor autoimmune disease, lupus, M&A, Merck & Co, Pandion Therapeutics, ulcerative colitis 0 Comment

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for

Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy

https://pharmaphorum.com/news/merck-takes-on-lilly-nektar-in-il-2-with-1-85bn-pandion-buy/

Market Access/ News/ News

GSK’s Benlysta claims first FDA okay for lupus kidney damage

Phil Taylor Benlysta, fda, GlaxoSmithKline, lupus, lupus nephritis 0 Comment

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up

GSK’s Benlysta claims first FDA okay for lupus kidney damage

https://pharmaphorum.com/news/gsks-benlysta-claims-first-fda-okay-for-lupus-kidney-damage/

Events/ Events/ Patients

PREDiCT: Autoimmune Disease Modeling Summit

jenna.warren@hansonwade.com autoimmune, Diabetes, IBD, lupus, Sclerosis 0 Comment

Deploy Advanced Models to Enhance Your Confidence & Und

PREDiCT: Autoimmune Disease Modeling Summit

https://pharmaphorum.com/events/predict-autoimmune-disease-modeling-summit/

News/ News/ R&D

AZ fleshes out positive trial of revitalised lupus drug anifrolumab

Phil Taylor AstraZeneca, autoimmune disease, Gazyvaro, lupus, lupus nephritis, Roche 0 Comment

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest

AZ fleshes out positive trial of revitalised lupus drug anifrolumab

https://pharmaphorum.com/news/az-fleshes-out-positive-trial-of-revitalised-lupus-drug-anifrolumab/

News/ News/ R&D

Gilead says arthritis drug filgotinib fails in follow-up use trials

Phil Taylor autoimmune disease, filgotinib, Galapagos, Gilead Sciences, JAK inhibitor, lupus 0 Comment

As Gilead and Galapagos prepare their JAK inhibitor filgotinib for a US filing in rheumatoid arthritis, the drug

Gilead says arthritis drug filgotinib fails in follow-up use trials

https://pharmaphorum.com/news/gilead-says-arthritis-drug-filgotinib-fails-in-follow-up-use-trials/

News/ News/ R&D

Could phase 3 trial win save AZ’s troubled Lupus drug?

Richard Staines AstraZeneca, GlaxoSmithKline, inflammatory diseases, lupus 0 Comment

AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a

Could phase 3 trial win save AZ’s troubled Lupus drug?

https://pharmaphorum.com/news/could-phase-3-trial-win-save-azs-troubled-lupus-drug/

News

Roche’s Gazyva shows promise in Lupus nephritis trial

Richard Staines lupus, R&D, Roche 0 Comment

Roche’s Gazyva is already approved in leukaemia and lymphoma – but could it work in the autoimmune kidney

Roche’s Gazyva shows promise in Lupus nephritis trial

https://pharmaphorum.com/news/roches-gazyva-shows-promise-in-lupus-nephritis-trial/

Trending

lupus

Login